Trials / Approved For Marketing
Approved For MarketingNCT03153462
Axicabtagene Ciloleucel Expanded Access Study
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Kite, A Gilead Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968
Conditions
- Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Relapsed/Refractory Primary Mediastinal B Cell Lymphoma
- Relapsed/Refractory Transformed Follicular Lymphoma
- Relapsed/Refractory High-Grade B-Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Axicabtagene Ciloleucel | Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously. |
Timeline
- First posted
- 2017-05-15
- Last updated
- 2023-11-08
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03153462. Inclusion in this directory is not an endorsement.